NEUTROGENA VISIBLY CLEAR LIGHT THERAPY ACNE MASK EU
Report
- Report Number
- 2214133-2018-00007
- Event Type
- Injury
- Date Received
- May 24, 2018
- Date of Event
- September 30, 2017
- Report Date
- April 30, 2018
- Manufacturer
- KINSENG PLASTICS CO. LTD.
- Product Code
- OLP
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- GM
- Reporter Occupation
- OTHER
Narratives
DEVICE WAS USED FOR TREATMENT, NOT DIAGNOSIS. WEIGHT AND ETHNICITY WERE NOT PROVIDED FOR REPORTING. DEVICE IS NOT DISTRIBUTED IN THE UNITED STATES, BUT IS SIMILAR TO DEVICE MARKETED IN THE USA (NTG LIGHT THERAPY ACNE MASK USA). (B)(4). LOT # WAS NOT PROVIDED. DEVICE IS NOT EXPECTED TO BE RETURNED FOR MANUFACTURER REVIEW/INVESTIGATION. DEVICE IS NOT DISTRIBUTED IN THE UNITED STATES, BUT IS SIMILAR TO DEVICE MARKETED IN THE USA (NTG LIGHT THERAPY ACNE MASK USA). (B)(4). DEVICE EVALUATION/INVESTIGATION COULD NOT BE COMPLETED; NO CONCLUSION COULD BE DRAWN AS PRODUCT WAS NOT RETURNED TO MANUFACTURER. DEVICE HISTORY RECORDS REVIEW COULD NOT BE COMPLETED WITHOUT LOT NUMBER. IF INFORMATION IS OBTAINED THAT WAS NOT AVAILABLE FOR THE INITIAL MEDWATCH, A FOLLOW-UP MEDWATCH WILL BE FILED AS APPROPRIATE.
A CONSUMER CALLED ABOUT THE NEUTROGENA VISIBLY CLEAR LIGHT THERAPY ACNE MASK SHE WAS USING FOR ACNE TREATMENT. THE CONSUMER STARTED USING THE DEVICE ON (B)(6) 2017 FOR DAILY TREATMENT. SINCE (B)(6) 2017 SHE IS ALLEGING THAT HER EYES HAVE BEEN DRY AND THAT SHE IS SENSITIVE TO THE SUNLIGHT. CONSUMER WAS SEEN BY A HEALTH CARE PROFESSIONAL WHO PRESCRIBED CORTISONE FOR TREATMENT. CONSUMER HAS ALSO BEEN USING A TEAR SUBSTITUTE FOR 2-3 MONTHS. CONSUMER IS ALLEGING DAMAGE TO THE CORNEAS AND SYMPTOMS ASSOCIATED WITH THE DISEASE SICCA (DRY EYES). SYMPTOMS HAVE NOT RESOLVED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 385035 | NEUTROGENA VISIBLY CLEAR LIGHT THERAPY ACNE MASK EU | ACNE LIGHT THERAPY SYSTEM | OLP | KINSENG PLASTICS CO. LTD. | AN3LTCMA11836 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 46 YR | Required Intervention | AMLODIPIN| OMEGA 3| VOLTAREN |